BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 16336095)

  • 1. Lymphocyte therapy of renal cell carcinoma.
    Dillman RO
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1041-51. PubMed ID: 16336095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective.
    Shablak A; Hawkins RE; Rothwell DG; Elkord E
    Clin Cancer Res; 2009 Nov; 15(21):6503-10. PubMed ID: 19843660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cell therapy in renal cell carcinoma].
    Ravaud A
    Bull Cancer; 2003; 90(8-9):711-21. PubMed ID: 14609761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An assessment of lymphocytic population in peripheral blood of patients with renal cell carcinoma before and after embolization.
    Osada J; Pietruczuk M; Dabrowska M; Kordecki K; Janica J; Walecki J
    Rocz Akad Med Bialymst; 2000; 45():228-39. PubMed ID: 11712434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immune anticancer response: recent advances in the treatment of renal cell carcinoma].
    Bouet F; Catros V
    Ann Biol Clin (Paris); 2004; 62(3):257-68. PubMed ID: 15217758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance].
    Han Y; Li CL; Lu L; Zhou CX; Ma WB; Wang DM; Zhang SR
    Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):158-60. PubMed ID: 15196436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for renal cell cancer.
    Yang JC; Childs R
    J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic stem cell transplantation for renal cell carcinoma.
    Bregni M; Herr W; Blaise D;
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):901-11. PubMed ID: 21707287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
    Markel G; Cohen-Sinai T; Besser MJ; Oved K; Itzhaki O; Seidman R; Fridman E; Treves AJ; Keisari Y; Dotan Z; Ramon J; Schachter J
    Anticancer Res; 2009 Jan; 29(1):145-54. PubMed ID: 19331144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells activated in vitro as immunotherapy for renal cell carcinoma: characterization of 2 effector T-cell populations.
    Garlie NK; Siebenlist RE; Lefever AV
    J Urol; 2001 Jul; 166(1):299-303. PubMed ID: 11435890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cell therapy for renal cell carcinoma].
    Kawai K
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1745-51. PubMed ID: 12402424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma.
    Takahashi Y; Childs RW
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6353S-9S. PubMed ID: 15448030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC; Belldegrun A; Figlin RA
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
    Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
    J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma.
    Strair RK; Schaar D; Medina D; Todd MB; Aisner J; DiPaola RS; Manago J; Knox B; Jenkinson A; Senzon R; Baker C; Liesel D; Ciardella M; Kuriyan M; Rubin A; Lattime EC
    J Clin Oncol; 2003 Oct; 21(20):3785-91. PubMed ID: 14551297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma.
    Viey E; Laplace C; Escudier B
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):973-86. PubMed ID: 16336088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG
    APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
    [No Abstract]   [Full Text] [Related]  

  • 20. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.
    Tassi E; Facchinetti V; Seresini S; Borri A; Dell'antonio G; Garavaglia C; Casorati G; Protti MP
    Clin Cancer Res; 2006 Aug; 12(16):4949-57. PubMed ID: 16914584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.